Cover Image
Market Research Report

Farxiga

Published by Datamonitor Healthcare Product code 603953
Published Content info 54 Pages
Delivery time: 1-2 business days
Price
Back to Top
Farxiga
Published: February 7, 2019 Content info: 54 Pages
Description

Overview

Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.

Table of Contents
Product Code: DMKC0080869

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Farxiga: Diabetic nephropathy
    • Farxiga: Diabetes type 1
    • Farxiga: Chronic heart failure (CHF)
    • Farxiga: Diabetes type 2

LIST OF FIGURES

  • Figure 1: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 3: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Farxiga for type 1 diabetes - SWOT analysis
  • Figure 5: Datamonitor Healthcare's drug assessment of Farxiga in type 1 diabetes
  • Figure 6: Datamonitor Healthcare's drug assessment of Farxiga in type 1 diabetes
  • Figure 7: Farxiga for chronic heart failure - SWOT analysis
  • Figure 8: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 10: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 11: Farxiga for type 2 diabetes - SWOT analysis
  • Figure 12: Datamonitor Healthcare drug assessment of Farxiga
  • Figure 13: Datamonitor Healthcare drug assessment scorecard for Farxiga compared to Januvia
  • Figure 14: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 15: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Farxiga drug profile
  • Table 2: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
  • Table 3: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
  • Table 4: Farxiga for diabetic nephropathy - SWOT analysis
  • Table 5: Farxiga drug profile
  • Table 6: Farxiga late-phase trials in type 1 diabetes
  • Table 7: Farxiga drug profile
  • Table 8: Farxiga Phase III trials in chronic heart failure
  • Table 9: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Farxiga franchise products
  • Table 11: Farxiga drug profile
  • Table 12: Xigduo drug profile
  • Table 13: Overview of pivotal trial data for Farxiga in diabetes
  • Table 14: Key planned and ongoing Phase III clinical trials for Farxiga in diabetes
  • Table 15: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 16: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Back to Top